A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC)

被引：2
|
作者：
Clayton, Ravinder
Heng, Daniel Yick Chin
Wu, Jackson S. Y.
Zielinski, Rob
North, Scott A.
Emmenegger, Urban
Hotte, Sebastien J.
Al-Shamsi, Humaid Obaid
Chen, Leo
Eigl, Bernhard J.
机构：
[1] Tom Baker Canc Clin, Calgary, AB, Canada
[2] British Columbia Canc Agcy, Vancouver Canc Ctr, Vancouver, BC V5Z 4E6, Canada
[3] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[4] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[5] Juravinski Canc Ctr, Hamilton, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.113
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
113
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA).
    Azad, Arun
    Lester, Renee
    Leibowitz-Amit, Raya
    Joshua, Anthony M.
    Heng, Daniel Yick Chin
    Eigl, Bernhard J.
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA)
    Azad, Arun
    Lester, Renee
    Leibowitz-Amit, Raya
    Joshua, Anthony Michael
    Heng, Daniel Yick Chin
    Eigl, Bernhard J.
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [3] Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC)
    Efstathiou, Eleni
    Titus, Mark Anton
    Wen, Sijin
    SanMiguel, Aileen
    Hoang, Anh
    De Haas-Amatsaleh, Angela
    Perabo, Frank
    De Phung
    Troncoso, Patricia
    Ouatas, Taoufik
    Logothetis, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] The effects of enzalutamide (ENZA) in combination with abiraterone acetate (AA) in patients with bone metastatic castration resistant prostate cancer (mCRPC)
    Efstathiou, E.
    Titus, M.
    Wen, A. S.
    San Miguel, A.
    Hoang, A.
    De Haas-Amatsaleh, A.
    Perabo, F.
    Phung, D.
    Troncoso, P.
    Logothetis, C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S680 - S681
  • [5] Indicators of clinical response to abiraterone acetate (AA) men with metastatic castration-resistant-prostate-cancer (mCRPC).
    Boegemann, Martin
    Mikah, Phillip
    Eminaga, Okyaz
    Herrmann, Edwin
    Papavassills, Philipp Marius
    Semjonow, Axel
    Krabbe, Laura-Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (AA)
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Bandekar, Rajesh
    Maneval, Edna Chow
    de Boer, Carla
    Todd, Mary
    Yu, Margaret K.
    Scher, Howard I.
    CANCER RESEARCH, 2014, 74 (19)
  • [7] CLINICAL ACTIVITY OF ABIRATERONE ACETATE (AA) AFTER PROGRESSION ON MDV3100 IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
    Noonan, K.
    Ellard, S.
    Chi, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 305 - 305
  • [8] Predictors of outcome to post-docetaxel abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (p)
    Ochoa de Olza, M.
    Font, A.
    Sala, N.
    Beltran, M.
    Barretina, P.
    Etxaniz, O.
    Indacoechea, A.
    Hernandez, A.
    Navarro, V.
    Germa, J. R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S701 - S701
  • [9] Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (MCRPC) after docetaxel chemotherapy: Multicentric experience of Anatolian Society of Medical Oncology
    Demirci, Umut
    Oflazoglu, Utku
    Kodaz, Hilmi
    Ciltas, Aydin
    Kefeli, Umut
    Akyol, Murat
    Ozturk, Banu
    Geredell, Caglayan
    Seker, Mehmet Metin
    Clhan, Saner
    Tastekin, Dldem
    Sevinc, Alper
    Akinci, Muhammad Bulent
    Uysal, Mukremin
    Taskoylu, Burcu Yapar
    Duran, Ayse Ocak
    Yazici, Omer Komi
    Karaoglu, Aziz
    Benekli, Mustafa
    Buyukberber, Suleyman
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] Primary resistance to abiraterone acetate (AA) after docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC): A multicenter retrospective analysis.
    Maruzzo, Marco
    Basso, Umberto
    Diminutto, Alberto
    De Giorgi, Ugo
    Fratino, Lucia
    Lo Re, Giovanni
    D'Angelo, Alessandro
    Donini, Maddalena
    Verderame, Francesco
    Ratta, Raffaele
    Procopio, Giuseppe
    Campadelli, Enrico
    Massari, Francesco
    Gasparro, Donatello
    Macrini, Sveva
    Messina, Caterina
    Giordano, Monica
    Maines, Francesca
    Zagonel, Vittorina
    Caffo, Orazio
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
12345